Siddharth Kaul, MD
Neurology · Bridgeton, MONPI 1245493402
Payments from drug & device makers
Across 1,267 payments — averaging $4500.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4.3M
- AbbVie$345K
- H. Lundbeck A S$238K
- Pfizer$170K
- Sage Therapeutics, LLC$135K
- Acadia Pharmaceuticals Inc$134K
- plus $378K from 29 others
Across 10 payments — averaging $5518.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$55K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 52 | $4,302,011 |
| AbbVie(2 entities) | 701 | $344,732 |
| H. Lundbeck A S | 87 | $238,142 |
| Pfizer | 99 | $170,030 |
| Sage Therapeutics, LLC | 3 | $135,331 |
| Acadia Pharmaceuticals Inc | 13 | $134,287 |
| Avanir Pharmaceuticals, Inc. | 36 | $108,982 |
| Biohaven Pharmaceutical Holding Company Ltd. | 34 | $59,045 |
| GSK | 20 | $58,096 |
| Ipsen Innovation | 36 | $48,362 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $33,432 |
| Eisai Inc. | 48 | $31,205 |
| Biohaven Pharmaceuticals, Inc. | 46 | $27,844 |
| Axsome Therapeutics, Inc. | 10 | $6,839 |
| Neurocrine Biosciences, Inc. | 20 | $695 |
| AstraZeneca | 5 | $618 |
| SK Life Science, Inc. | 8 | $489 |
| Biogen | 9 | $441 |
| E.r. Squibb & Sons, L.L.C. | 5 | $400 |
| Genentech USA, Inc. | 2 | $247 |
| Otsuka America Pharmaceutical, Inc. | 3 | $209 |
| Bristol Myers Squibb | 5 | $137 |
| TG Therapeutics, Inc. | 1 | $136 |
| MDD US Operations, LLC | 2 | $128 |
| Greenwich Biosciences, Inc. | 1 | $126 |
| Averitas Pharma Inc. | 1 | $105 |
| Sunovion Pharmaceuticals Inc. | 1 | $88 |
| Novartis | 5 | $81 |
| Merck | 2 | $68 |
| Upsher-smith Laboratories LLC | 2 | $51 |
| Lundbeck LLC | 2 | $45 |
| EMD Serono, Inc. | 2 | $29 |
| Lilly USA, LLC | 2 | $25 |
| Johnson & Johnson | 1 | $19 |
| Assertio Therapeutics, Inc. | 1 | $13 |
How this compares
$5,702,490 in reported general payments places this provider in the 95th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Bridgeton
- Daniel MattsonBridgeton$478K
- Seth HepnerBridgeton$406K
- Randall BatemanSaint Louis$92.3M
- David HoltzmanSaint Louis$25.2M
- Robert NaismithSaint Louis$13.8M
- Eric McDadeSaint Louis$9.6M
- Robert BucelliSaint Louis$8.5M
- Barbara SniderSaint Louis$7M
- Curtis SchreiberBolivar$6.4M
- Gregory WuSaint Louis$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.